abcelleraq32023businessu

C O P Y R IG H T © A B C E LL E R A Q3 2023 BUSINESS UPDATE NOVEMBER 2, 2023

C O PY RI G H T © A B C EL LE RA DISCLAIMER 2 This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Q 3 2 0 2 3 B U S IN ES S U PD AT E

C O PY RI G H T © A B C EL LE RA C O PY RI G H T © A B C EL LE RA 3 Q 3 2 0 2 3 B U S IN ES S U PD AT E Q 3 2 0 2 3 . B U S I N E S S U P D AT E S U M M A R Y. Continued focus on high-value programs & strategic partnerships cumulative programs under contract in total cash, cash equivalents, & marketable securities cumulative partnered programs started molecules in the clinic $813M 110 182 10

C O PY RI G H T © A B C EL LE RA C O PY RI G H T © A B C EL LE RA Two AbCellera-led programs advancing into IND-enabling studies. 4 Q 3 2 0 2 3 B U S IN ES S U PD AT E P R O G R A M S MOLECULE TARGET INDICATION THERAPEUTIC AREA POTENTIAL DIFFERENTIATION POTENTIAL MARKET SIZE ABCL575 OX40L atopic dermatitis immunology and inflammation best in class $17B by 2032* ABCL635 undisclosed GPCR or ion channel undisclosed metabolic and endocrine conditions first in class >$2B * Source: IQVIA

C O PY RI G H T © A B C EL LE RA C O PY RI G H T © A B C EL LE RA Strategic collaborations with new and existing partners. 5 Q 3 2 0 2 3 B U S IN ES S U PD AT E P A R T N E R S H I P S 1 program under contract8 programs under contract 4 new 2 completed Regeneron has exercised its rights to advance antibody candidates into further preclinical developmentMULTIPLE INDICATIONS ONCOLOGY

C O PY RI G H T © A B C EL LE RA C O PY RI G H T © A B C EL LE RA 6 Q 3 2 0 2 3 B U S IN ES S U PD AT E Delivering on stated business objectives. candidates for IND-enabling studies strategic partnerships T-cell engager platform P R I O R I T I E S ELECT EXECUTE ADVANCE

C O P Y R IG H T © A B C E LL E R A Q3 2023 FINANCIALS UPDATE

C O PY RI G H T © A B C EL LE RA 0 10 20 30 40 50 60 70 80 90 100 110 18 19 20 21 22 23 Q3 17162015 110 Continuing portfolio growth. 8 FI N A N CI A LS Partnered Program Starts Cumulative # of + WITH downstream participation – WITHOUT downstream participation Molecules in the Clinic Cumulative # of Discovery Partners Programs Under Contract 182 Total # of Total # of 42 10 1 2 3 4 5 6 7 8 9 10 0 19 20 21 22 23 Q3 18172015 16 Q 3 2 0 2 3 B U S IN ES S U PD AT E

C O PY RI G H T © A B C EL LE RA FINANCIALS 9 Q 3 2 0 2 3 B U S IN ES S U PD AT E FI N A N CI A LS Now 10 molecules in the clinic. MOLECULE STAGE THERAPEUTIC AREA PARTNER PROGRAM TYPE bamlanivimab (LY-CoV555) Marketed, Emergency Use Authorization (EUA) • infectious disease: COVID-19 AbCellera-initiated program PARTNERED bebtelovimab (LY-CoV1404) Marketed, Emergency Use Authorization (EUA) • infectious disease: COVID-19 TAK-920/DNL919 Phase 1 • neurology: Alzheimer’s Disease AbCellera partner-initiated discovery undisclosed Phase 1 • neuroscience undisclosed Phase 1 • undisclosed undisclosed Trianni license NBL-012 Phase 1 • dermatology • gastrointestinal disease • immunology NBL-015/FL-301 Phase 1 • oncology NBL-020 Phase 1 • oncology NBL-028 IND/CTA authorized • oncology IVX-01 Clinical field study • animal health AbCellera partner-initiated discovery NEW

C O PY RI G H T © A B C EL LE RA 10 Q 3 2 0 2 3 B U S IN ES S U PD AT E FI N A N CI A LS $7M total revenue, predominantly from discovery activity. MILESTONES ROYALTIES LICENSING RESEARCH FEES Revenue USD Q3 2022 $6.6M $7.5M Q3 2023 $0.2M $6.4M $101.4M

C O PY RI G H T © A B C EL LE RA 11 Q 3 2 0 2 3 B U S IN ES S U PD AT E FI N A N CI A LS Operating expenses reflect ongoing investments, predominantly in R&D. RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN Operating Expenses USD Q3 2023Q3 2022 $3.1M $3.5M +$0.4M Q3 2023Q3 2022 $13.8M $14.4M +$0.6M Q3 2023Q3 2022 $26.6M $37.9M +$11.3M

C O PY RI G H T © A B C EL LE RA 12 Q 3 2 0 2 3 B U S IN ES S U PD AT E FI N A N CI A LS Net loss of $29M; equivalent to ($0.10) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC Q3 2022 Q3 2023 $26.6M -$28.6M $0.09 -$0.10 Q3 2022 Q3 2023 EARNINGS PER SHARE: DILUTED $0.08 -$0.10 Q3 2022 Q3 2023

C O PY RI G H T © A B C EL LE RA 13 Q 3 2 0 2 3 B U S IN ES S U PD AT E FI N A N CI A LS Over $800M in total cash, equivalents, and marketable securities. Cash Flows USD INVESTING FINANCING $95M Other FX $613M Marketable Securities $172M Cash & Equivalents $500M Marketable Securities September 30, 2023 $102M Marketable Securities (net) OPERATINGDecember 31, 2022 $28M* $387M Cash & Equivalents $915M ($24M) ($197M) $7M $0M $813M $27M*

C O PY RI G H T © A B C EL LE RA • ABCL575 targets the OX40 ligand (OX40L) and has been designed as a potential best-in-class therapy for atopic dermatitis and other indications in autoimmunity and inflammation. • ABCL575 was discovered as part of AbCellera’s 2021 co-development collaboration with EQRx. • AbCellera took ownership of the program in Q3 2023. • ABCL575 has been designed with potency, PK, and developability to enable less-frequent dosing than benchmark molecules. • ABCL635 is the first pipeline asset from the company’s GPCR and Ion Channel platform. • ABCL635 hits an undisclosed target with an indication in metabolic and endocrine disorders. • Overall market estimated at over $2 billion in annual sales. • AbCellera anticipates potential IND submissions for ABCL575 and ABCL635 in 2025. • AbCellera anticipates additional development candidates from AbCellera-led programs to advance into late-stage preclinical and IND-enabling studies in 2024 and 2025. 1 Q 3 2 0 2 3 B U S IN ES S U PD AT E EA RN IN G S CA LL S U M M A RY EARNINGS CALL SUMMARY Note: This document contains a condensed summary of AbCellera’s 2023-11-02 earnings call. It should be read in conjunction with, and in the context of, the contents of the call itself. AbCellera achieves a significant company milestone, advancing two assets, ABCL575 and ABCL635, from AbCellera-led programs into IND-enabling studies.

C O PY RI G H T © A B C EL LE RA 2 Q 3 2 0 2 3 B U S IN ES S U PD AT E EA RN IN G S CA LL S U M M A RY • AbCellera announced a new partnership with Incyte, with one new program under contract for an indication in oncology. • AbCellera expanded its existing partnership with Regeneron, with four new programs under contract. • Under its original agreement with AbCellera, Regeneron exercised its rights to advance antibody candidates from two completed discovery programs, including one against a GPCR target. • AbCellera announced a new co-development partnership with Prelude to develop novel, precision antibody-drug conjugates (ADCs) for oncology. AbCellera maintains committed to accelerating high-value programs from strategic partnerships, and announced new and expanded collaborations with new and existing strategic partners. AbCellera’s financial position continues to strongly support execution of strategy, including investments in downstream capabilities and pre-clinical- and early-clinical development of assets. • Business Metrics – 4 new program starts in Q3 2023, for a cumulative total of 110 with 42 unique partners; one molecule advanced into the clinic, bringing the cumulative total to ten. • Revenue – Approximately $7 million in total revenue, driven by research fees generated by the partnership business. • Operating Expenses – • Approximately $38 million in R&D expenses, reflecting growth in program execution, continuing platform development, and investment in internal programs. • Approximately $4 million in S&M expenses. • Approximately $14 million in G&A expenses, reflecting good operating leverage. • Earnings – Net loss of approximately $29 million, reflective of continued investment in the business in the absence of royalty revenues. • Cash Flows – With over $800 million in total cash, cash equivalents, and marketable securities as well as unused portion of previously-secured government funding, AbCellera continues to have over $1 billion in total available liquidity.